

CURRICULUM VITAE

Lili Zhao

Office: Department of Biostatistics, University of Michigan
1415 Washington Heights, M2541 SPH II
Ann Arbor, Michigan 48109
Phone: (734) 763-6898
Fax: (734) 763-2215
E-mail: zhaolili@umich.edu

Education:

Ph.D.	Statistics	University of Iowa	2006
M.S.	Statistics	University of Iowa	2003
B.S.	Marketing & Economics	The Capital University of Economics & Business, Beijing, China	1999

Professional Experience:

2018(Sep.)	Research Associate Professor Department of Biostatistics, University of Michigan
2014-2018	Research Assistant Professor Department of Biostatistics, University of Michigan
2011-2014	Research Investigator Department of Biostatistics, University of Michigan
2007-2011	Statistician Lead Comprehensive Cancer Center, University of Michigan
2006-2007	Senior Statistician Becton, Dickinson and Company, Baltimore, MD
2004-2006	Research Assistant Statistical Consulting Center, University of Iowa
2003-2005	Research Assistant Women in Science and Engineering (WISE), University of Iowa
2002	Research Assistant Department of Epidemiology, University of Iowa
2001-2004	Teaching Assistant Department of Statistics and Actuarial Science, University of Iowa
2000-2001	Teaching Assistant Department of Mathematics and Statistics, Syracuse University

Statistical Areas of Interest:

Bayesian Statistics; Survival Analysis; Clinical Trial Designs; Nonparametric Bayesian Methods; RNA-Seq Data Analysis; Change-point Analysis; Mixture Models; Multivariate Analysis; Graphical models; Longitudinal data analysis

Awards and Honors:

2006 Graduate College Summer Fellowship, University of Iowa

2016 Woodson Biostatistics Award, University of Michigan

Peer-reviewed Publications(*published, in press or accepted*):

1. Kilbane KS, Girgla N, **Zhao L**, Barnett SL, Berezovsky A, Lagisetty K, Lin J, Reddy RM. (2021). Adaptive and Maladaptive Coping Mechanisms Used by Patients With Esophageal Cancer After Esophagectomy. *J Surg Res.* 258:1-7.
2. **Zhao L**. (2021). Deep neural networks for predicting restricted mean survival times. *Bioinformatics* in Press.
3. **Zhao L** and Carl Koschmann. (2020). Integrating subgroups with mixed-type endpoints in early phase oncology trials. *Statistical Methods in Medical Research*, 29(2):498–507.
4. **Zhao L** and Dai Feng. (2020). Deep Neural Networks for Survival Analysis Using Pseudo Values. *IEEE J Biomed Health Inform*, 24(11): 3308-3314.
5. **Zhao L**, Lee S, Li R, Ong E, He Y and Freed G. (2020). Improvement in the Analysis of Vaccine Adverse Event Reporting System Database. *Statistics in Biopharmaceutical Research*, 12(3):303–310.
6. **Zhao L**, Murray S, Mariani LH, and Ju W. (2020). Incorporating longitudinal biomarkers for dynamic risk prediction in the era of big data: A pseudo-observation approach. *Statistics in Medicine*, 39(26): 3685-3699.
7. Tapper EB, **Zhao L**, Nikirk S, Baki J, Parikh ND, Lok AS, and Waljee AK. (2020). Incidence and bedside predictors of the first episode of overt hepatic encephalopathy in patients with cirrhosis. *Official journal of the American College of Gastroenterology ACG*, 115(12), 2017-2025.
8. Agrawal D, Raghavendran K, **Zhao L**, and Rajajee V. (2020). A Prospective Study of Optic Nerve Ultrasound for the Detection of Elevated Intracranial Pressure in Severe Traumatic Brain Injury. *Care Medicine*, 48(12): e1278-e1285.
9. Azam TU, Shadid HR, Blakely P, O’Hayer P, Berlin H, Pan M, Zhao P, **Zhao L**, Penathur S, Pop-Busui R, Altintas I, Tingleff J, Stauning MA, Andersen O, Adami ME, Solomonidi N, Tsilika M, Tober-Lau P, Arnaoutoglou E, Keitel V, Tacke F, Chalkias A, Loosen SH, Giamarellos-Bourboulis EJ, Eugen-Olsen J, Reiser J, Hayek SS. (2020) Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. *J Am Soc Nephrol*. 31(11):2725-2735
10. Qin A, Rengan R, Lee S, Santana-Davila R, Goulart BHL, Martins R, Baik C, Kalemkerian GP, Hassan KA, Schneider BJ, Hayman JA, Jolly S, Hearn J, Lawrence TS, Towler-ton AMH, Tewari M, Thomas D, **Zhao L**, Brown N, Frankel TL, Warren EH, Ramnath N. (2020) A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys*. 108(1), 170-177.

11. Williams AM, **Zhao L**, Grenda TR, Kathawate RG, Biesterveld BE, Bhatti UF, Carrott PW, Lagisetty KH, Chang AC, Lynch W, Lin J, Reddy RM. (2020) Higher Long-Term Quality of Life Metrics After VATS Lobectomy Compared to Robotic-Assisted Lobectomy. *Ann Thorac Surg.* June 26.
12. Shea AE, Marzoa J, Himpsl SD, Smith SN, **Zhao L**, Tran L, Mobley HLT. (2020) Escherichia coli CFT073 Fitness Factors during Urinary Tract Infection: Identification Using an Ordered Transposon Library. *Environ Microbiol.* 17;86(13).
13. Sen A, **Zhao L**, Djuric Z, Turgeon DK, Ruffin MT, Smith WL, Brenner DE, Normolle DP. (2020) An Adaptive Bayesian Design for Personalized Dosing in a Cancer Prevention Trial. *Am J Prev Med.* 59(4):e167-e173.
14. Zeinali M, Lee M, Nadhan A, Nathur A, Hedman C, Lin E, Harouaka R, Wicha MS, **Zhao L**, et al.(2020). High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients . *Cancers (Basel)* , 12(1):127.
15. Yu AI, **Zhao L**, Eaton KA, Schloss PD, Martens EC, and Chen GY. (2020). Gut Microbiota Modulate CD8 T Cell Responses to Influence Colitis-Associated Tumorigenesis. *Cell Reports*, 31(1):107471.
16. Skala SL, Ebott JA, **Zhao L** and Lieberman RW. (2020). Predictive Value of an Alternative Strategy for Measuring Depth and Size of Stage 1 Vulvar Squamous Cell Carcinoma. *Journal of Lower Genital Tract Disease.* 3: 265-271.
17. Panarelli NC, Hammer STG, Lin J, Gopal P, Nalbantoglu I, **Zhao L** cheng J, Gersten A, McHugh J, Parkash V, Lucas E and Westerhoff M (2020). Reproducibility of American Joint Committee on Cancer Criteria for Classifying Deeply Invasive Colonic Adenocarcinomas is a Persistent Problem in Cancer Staging. *American Journal of Surgical Pathology*, 10 (2020): 1381-1388.
18. Alghamri MS, Thalla R, Avvari R, Dabaja A, Taher A, **Zhao L**, Ulintz PJ, Castro MG and Lowenstein PR.(2020). Tumor Mutational Burden Predicts Survival in Patients with Low Grade Gliomas Expressing Mutated IDH1. *Neuro-Oncology Advances.* (2020). 2(1): vdaa042.
19. Feng S, Zhou J, Li Z, Appelman HD, **Zhao L**, Zhu J, Wang TD. (2019). Sorafenib encapsulated in nanocarrier functionalized with glypican-3 specific peptide for targeted therapy of hepatocellular carcinoma. *Colloids Surf B Biointerfaces*, 184: 110498.
20. Foote DC, Burke CR, Pandian B, Banks S, Haug KL, Hipp M, **Zhao L**, Smola B, Roh M, Carrott PW Jr, Lynch WR, Chang AC, Lin J, and Reddy RM. (2019) Gender Disparity in Referral for Definitive Care of Malignant Pleural Effusions. *Journal of Surgical Research*, 244: 409-416.
21. Ettel M, **Zhao L**, Schechter S, Shi J. (2019) Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions. *Pathology*, 51(4):392-398.
22. Armbruster CE, Forsyth VS, Johnson AO, Smith SN, White AN, Brauer AL, Learman BS, **Zhao L** et al. (2019). Twin arginine translocation, ammonia incorporation,

- and polyamine biosynthesis are crucial for *Proteus mirabilis* fitness during bloodstream infection. *PLoS Pathog.*, 15(4): e1007653.
23. Hlavaty L, Roquero L, Amley J, Root K, Ishikawa M, Koopmeiners A, **Zhao L**, Sung L. (2019). Discordance of Gross and Histologic Findings in Estimating the Range of Fire of Gunshot Wounds. *J Forensic Sci*, 64(5):1399-1411.
 24. Vornhagen J, Sun Y, Breen P, Forsyth V, **Zhao L**, Mobley HLT, Bachman MA. (2019). The *Klebsiella pneumoniae* citrate synthase gene, *gltA*, influences site specific fitness during infection. *PLoS Pathog*, 15(8): e1008010.
 25. Chan, MP, Plouffe, KR, Liu, C, Palanisamy N, Carskadon S, **Zhao L**, Nazarian RM, Durham Alison, Johnson TM, Andea AA, Patel RM, Lowe L, Fullen DR, Brown NA, Tomlins SA, Udager AM and Harms PW. (2019). Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas. *Modern Pathology*
 26. Zafar MA, Hammond AJ, Hamaguchi S, Wu W Kono M, **Zhao L**, Weiser JN. (2019). Identification of Pneumococcal Factors Affecting Pneumococcal Shedding Shows that the *dlt* Locus Promotes Inflammation and Transmission. *mBio*, 10(3): e01032-19.
 27. Altshuler DB, Wang L, **Zhao L**, Miklja Z, Linzey J, Brezzell, et.al. (2019). BDNF, COMT, and DRD2 polymorphisms and ability to return to work in adult patients with low-and high-grade glioma. *Neuro-oncology practice*. 6(5): 375-385.
 28. Wang Y, Kim TH, Fouladdel S, Zhang Z, Soni P, Qin A, **Zhao L** et. al. (2019). PD-L1 expression in circulating tumor cells increases during radio (chemo) therapy and indicates poor prognosis in non-small cell lung cancer. *Scientific reports*. 9(1): 1-9.
 29. Núñez FJ, Mendez FM, Kadiyala P, Alghamri MS, Savelieff MG, Garcia-Fabiani MB, Haase S, Koschmann C, Calinescu AA, Kamran N, Saxena M, Patel R, Carney S, Guo MZ, Edwards M, Ljungman M, Qin T, Sartor MA, Tagett R, Venneti S, Brosnan-Cashman J, Meeker A, Gorbunova V, **Zhao L**, Kremer DM, Zhang L, Lyssiotis CA, Jones L, Herting CJ, Ross JL, Hambardzumyan D, Hervey-Jumper S, Figueroa ME, Lowenstein PR, Castro MG (2019). IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. *Sci Transl Med.*, 11(479).
 30. Siontis BL, **Zhao L**, Leja M, McHugh JB, Shango MM, Baker LH, Schuetze SM, and Chugh R (2019). Primary Cardiac Sarcoma: A Rare, Aggressive Malignancy with a High Propensity for Brain Metastases. *Sarcoma*, 2019:1-6.
 31. Zhou Q, Li H, Li Y, Tan M, Fan S, Cao C, Meng F, Zhu L, **Zhao L**, Guan MX, Jin H, Sun Y (2019). Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells. *JCI Insight*, 4(4).
 32. **Zhao L**, Wu W, Feng D, Jiang H and Nguyen X. (2018). Bayesian Analysis of RNA-Seq Data Using a Family of Negative Binomial Models. *Bayesian Analysis*, 13(2): 411–436.
 33. Linzey J, Bernard M, Pasternak A, Smith C, Miklja Z, **Zhao L**, Kumar-Sinha C, Paul A, Harris N, Robertson P, Hoffman L, Chinnaiyan, Mody R and Koschmann C. Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology (2018). *J Neuro-Oncology*, 137 (1): 155-169.

34. Skala SL, Arps DP, **Zhao L**, Cha KB, Wang M, Harms PW, Andea AA, Fullen DR, Chan MP (2018). Comprehensive histopathological comparison of epidermotropic/dermal metastatic melanoma and primary nodular melanoma. *Histopathology*, 72(3):472-480.
35. Muller KE, **Zhao L**, Jorns JM (2018). Isolated Atypical Lobular Hyperplasia Diagnosed on Breast Biopsy: Low Upgrade Rate on Subsequent Excision with Long-Term Follow-up. *Archives of Pathology and Laboratory Medicine*, 142(3):391-395.
36. Mor-Vaknin N, Rivas M, Legendre M, Mohan S, Yuanfan Y, Mau T, Johnson A, Huang B, **Zhao L**, Kimura Y, Spalding SJ, Morris PW, Gottlieb BS, Onel K, Olson JC, Edelheit BS, Shishov M, Jung LK, Cassidy EA, Prahalad S, Passo MH, Beukelman T, Mehta J, Giannini EH, Adams BS, Lovell DJ, Markovitz DM (2018). High levels of DEK autoantibodies in sera of polyarticular JIA patients and in early flare following cessation of anti-TNF therapy. *Arthritis Rheumatol*, 70(4):594-605.
37. East E, Gabbeart M, Roberts E, and **Zhao L** and Jorns J (2018). A Rapid Triage Protocol to Optimize Cold Ischemic Time for Breast Resection Specimens. *Annals of Diagnostic Pathology*, 34:94-97.
38. Ropa J, Saha N, Chen Z, Serio J, Chen W, Mellacheruvu D, **Zhao L**, Basrur V, Nesvizhskii AI and Muntean AG (2018). PAF1 complex interactions with SETDB1 mediate promoter H3K9 methylation and transcriptional repression of Hoxa9 and Meis1 in acute myeloid leukemia. *Oncotarget*, 9(31):22123-22136.
39. Sherbeck JP, **Zhao L**, Lieberman RW (2018). High Variability in Lymph Node Counts Among an International Cohort of Pathologists: Questioning the Scientific Validity of Node Counts. *J Natl Compr Canc Netw.*, 16(4):395-401.
40. Asirvatham JR, **Zhao L**, Jeffries DO, Jorns JM, and Wu AJ. (2018). Outcomes of Benign Intraductal Papillomas Diagnosed on Core Biopsy: A Review of 104 Cases with Subsequent Excision from a Single Institution. *Archives of Pathology and Laboratory Medicine.*, 73(6):679-686.
41. Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, Wei S, **Zhao L**, Vatan L, Wen B, Shu P, Sun D, Kleer C, Wicha M, Sabel M, Tao K, Wang G, Zou W (2018). Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. *Cell Metab.*, 28(1):87-103.
42. Gits HC, Anderson M, Stallard S, Pratt D, Zon B, Howell C, Kumar-Sinha C, Vats P, Kasaian K, Polan D, Matuszak M, Spratt DE, Leonard M, Qin T, **Zhao L**, Leach J, Chaney B, Escorza NY, Hendershot J, Jones B, Fuller C, Leary S, Bartels U, Bouffet E, Yock TI, Robertson P, Mody R, Venneti S, Chinnaiyan AM, Fouladi M, Gottardo NG, Koschmann C (2018). Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. *Acta Neuropathol Commun.*, 6(1):67.
43. Anderson MT, Mitchell LA, Zhao L, Mobley HLT (2018). *Citrobacter freundii* fitness during bloodstream infection. *Sci Rep.*, 8(1):11792.
44. Heiden BT, Patel N, Nancarrow DJ, Hermann M, Brown RKJ, Orringer MB, Lin J, Chang AC, Carrott PW, Lynch WR, **Zhao L**, Beer DG, Reddy RM (2018). Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake Correlates with KRAS and EMT Gene Signatures in Operable Esophageal Adenocarcinoma. *J Surg Res.*, 232:621-628.

45. Bailey KM, Durham AB, **Zhao L**, Fullen D, Geiger J, Bradford C, et al. (2018). Pediatric melanoma and aggressive Spitz tumors: a retrospective diagnostic, exposure and outcome analysis. *Transl Pediatr.*, 7(3): 203–210.
46. Lin H, Wei S, Hurt EM, Green MD, **Zhao L**, Vatan L, et al. (2018). Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. *J Clin Invest.*, 128(2): 805–815.
47. **Zhao L**, Anderson MT, Wu W, Mobley HLT, and Bachman MA. (2017). TnseqDiff: Identification of Conditionally Essential Genes in Transposon Sequencing Studies. *BMC Bioinformatics*, 18(1):326-336.
48. Qin A, Street L, Cease K, Viglianti BL, Warren EH, **Zhao L**, and Ramnath N. (2017). Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. *Clin Lung Cancer*, S1525-7304(17): 30041-4.
49. Kwon ST, **Zhao L**, Reddy RM, Chang AC, Orringer MB, Brummett CM, and Lin J. (2017). Evaluation of Acute and Chronic Pain Outcomes After Robotic, Video-assisted Thoracoscopic Surgery, or Open Anatomic Pulmonary Resection. *J Thorac Cardiovasc Surg*, S0022-5223(17): 30216-30217.
50. Wahl DR, Dresser J, Wilder-Romans K, Parsels JD, Zhao SG, Davis M, **Zhao L**, Kachman M, Wernisch S, Burant CF, Morgan MA, Feng FY, Speers C, Lyssiotis CA, and Lawrence TS. (2017) Glioblastoma Therapy can be Augmented by Targeting IDH1-mediated NADPH Biosynthesis. *Cancer Research*, 77(4):960-970.
51. Wang GY, Nazarian RM, **Zhao L**, Hristov AC, Patel RM, Fullen DR, and Chan MP. (2017). Protein Gene Product 9.5 (PGP9.5) Expression in Benign Cutaneous Mesenchymal, Histiocytic, and Melanocytic Lesions: Comparison with Cellular Neurothekeoma. *Pathology*, 49(1):44-49.
52. Shiratsuchi H, Wang Z, Chen G, Ray P, Lin J, Zhang Z, **Zhao L**, Beer D, Ray D, and Ramnath N. (2017). Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma. *J Thorac Oncol*, 12(2):269-280.
53. Anderson MT, Mitchell LA, **Zhao L**, and Mobley HLT. (2017). Capsule Production and Glucose Metabolism Dictate Fitness During *Serratia Marcescens* Bacteremia. *MBio.*, 8(3): e00740-17.
54. Li H, Zhou W, Li L, Wu J, Liu X, **Zhao L**, Jia L, and Sun Y. (2017). Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine. *Neoplasia*, 19(6):509-518.
55. Seregin SS, Golovchenko N, Schaf B, Chen J, Pudlo NA, Mitchell J, Baxter NT, **Zhao L**, Schloss PD, Martens EC, Eaton KA, and Chen GY. (2017). NLRP6 Protects Il10^{-/-} Mice from Colitis by Limiting Colonization of *Akkermansia muciniphila*. *Cell Rep.*, 19(4):733-745.
56. East EG, **Zhao L**, Pang JC, Jorns JM. Characteristics of a Breast Pathology Consultation Practice. (2017). *Archives of Pathology & Laboratory Medicine*, 141(4):578-584.

57. Mody R, **Zhao L**, Yanik GA, and Opipari. (2017). Phase I Study of Bortezomib in Combination with Irinotecan in Patients with Relapsed/Refractory High-risk Neuroblastoma. *Pediatric Blood Cancer*, 64(11).
58. Boonstra PS, Braun TM, Taylor JMG, Kidwell KM, Bellile EL, Daignault S, **Zhao L**, Griffith KA, Lawrence TS, Kalemkerian GP, and Schipper MJ (2017). Statistical Controversies in Cancer Research: Building the Bridge to Phase II: Efficacy Estimation in Dose-expansion Cohorts. *Annals of Oncology*,28(7):1427-1435
59. Armbruster CE, Forsyth-DeOrnellas V, Johnson AO, Smith SN, **Zhao L**, Wu W, and Mobley HLT. (2017). Genome-wide Transposon Mutagenesis of *Proteus Mirabilis*: Essential Genes, Fitness Factors for Catheter-associated Urinary Tract Infection, and The Impact of Polymicrobial Infection on Fitness Requirements. *PLOS pathogens*, 13(6): e1006434.
60. Savastano LE, Zhou Q, Smith A, Vega K, Murga-Zamalloa C, Gordon D, McHugh J, **Zhao L**, Wang M, Pandey A, Thompson BG, Xu J, Zhang J, Chen YE, Seibel EJ, and Wang TD. (2017). Multimodal Laser-based Angioscopy for Structural, Chemical and Biological Imaging of Atherosclerosis. *Nature Biomedical Engineering*, 1: 0023..
61. Durham AB, Schwartz JL, Lowe L, **Zhao L**, Johnson AG, Harms KL, Bichakjian CK, Orsini AP, McLean SA, Bradford CR, Cohen MS, Johnson TM, Sabel MS, and Wong SL.(2017). The Natural History of Thin Melanoma and the Utility of Sentinel Lymph Node Biopsy. *Journal of Surgical Oncology*,116(8):1185-1192
62. East EG, Gast K, Kuzon W, Roberts E, **Zhao L**, Jorns JM. (2017). Clinicopathologic Findings in Female to Male Gender Affirming Breast Surgery. *Histopathology*,71(6):859-865.
63. Murlidhar V, Reddy RM, Fouladdel S, **Zhao L**, Ishikawa MK, Grabauskiene S, Zhang Z, Lin J, Chang AC, Carrott P, Lynch WR, Orringer MB, Kumar-Sinha C, Palanisamy N, Beer DG, Wicha MS, Ramnath N, Azizi E, Nagrath S (2017). Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early Stage Lung Cancers. *Cancer Research*,77(18):5194-5206.
64. Djuric Z, Turgeon DK, Sen A, Ren J, Herman K, Ramaswamy D, **Zhao L**, Ruffin MT, Normolle DP, Smith WL, Brenner DE (2017). The Anti-inflammatory Effect of Personalized Omega-3 Fatty Acid Dosing for Reducing Prostaglandin E2 in the Colonic Mucosa Is Attenuated in Obesity. *Cancer Prev Res (Phila)*, 10(12):729-737.
65. Harms KL, Chubb H, **Zhao L**, Fullen DR, Bichakjian CK, Johnson TM, Carskadon S, Palanisamy N, Harms PW (2017). Increased expression of EZH2 in Merkel cell carcinoma is associated with disease progression and poorer prognosis. *Hum Pathol.*, 67:78-84.
66. Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S, **Zhao L**, Vatan L, Shao I, Szeliga W, Lyssiotis C, Liu JR, Kryczek I, Zou W (2017). Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor.*Nat Immunol*, 18(12):1332-1341.
67. Siontis B, Roberts E, **Zhao L**, McHugh JB, Owen D, Baker LH, Biermann JS, Schuetze S, and Chugh R (2017). Radiation-associated versus sporadic osteosarcoma: A single-institution experience. *Journal of Clinical Oncology*, 35(15):11018-11018.

68. **Zhao L**, Feng D, Chen G, and Taylor JM. (2016). A Unified Bayesian Semiparametric Approach to Assess Discrimination Ability in Survival Analysis. *Biometrics*, 72(2):554-62.
69. Giorgetti E, Yu Z, Chua JP, Shimamura R, **Zhao L**, Zhu F, Venneti S, Pennuto M, Guan Y, Hung G, and Lieberman AP. (2016). Rescue of Metabolic Alterations in AR113Q Skeletal Muscle by Peripheral Androgen Receptor Gene Silencing. *Cell Rep.*, 17(1): 125-136.
70. Harms PW, Hocker TL, **Zhao L**, Chan MP, Andea AA, Wang M, Harms KL, Wang ML, Carskadon S, Palanisamy N, and Fullen DR. (2016). Loss of p16 Expression and Copy Number Changes of CDKN2A in a Spectrum of Spitzoid Melanocytic Lesions. *Hum Pathol*, 58:152-160.
71. Ramon DS, Huang Y, **Zhao L**, Rendulic T, Park JM, Sung RS, and Samaniego M. (2016). Use of Complement Binding Assays to Assess the Efficacy of Antibody Mediated Rejection Therapy and Prediction of Graft Survival in Kidney Transplantation. *Human Immunology*, 78:57-63.
72. Davis EJ, **Zhao L**, Lucas DR, Schuetze SM, Baker LH, Zalupski MM, Thomas D, and Chugh R. (2016). SPARC Expression in Patients with High-risk Localized Soft Tissue Sarcoma Treated on a Randomized Phase II Trial of Neo/adjuvant Chemotherapy. *BMC Cancer*, 16-663.
73. Yamada C, Pipe SW, **Zhao L**, Leichtman AB, Samaniego M, Sung RS, and Davenport RD. (2016). Coagulation Status After Therapeutic Plasma Exchange Using Citrate in Kidney Transplant Recipients. *Transfusion*, 56(2): 3073-3080.
74. Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, **Zhao L**, Bixby D, Peterson L, Camelo-Piragua S, Jones C, Mody R, Lowenstein PR, and Castro MG. (2016). Characterizing and Targeting PDGFRA Alterations in Pediatric High-grade Glioma. *Oncotarget*, 7(40): 65696-65706.
75. Peng D, Tanikawa T, Li W, **Zhao L**, Vatan L, Szeliga W, Wan S, Wei S, Wang Y, Liu Y, Staroslawska E, Szubstarski F, Rolinski J, Grywalska E, Stanislawek A, Polkowski W, Kurylcio A, Kleer C, Chang AE, Wicha M, Sabel M, Zou W, and Kryczek I. (2016). Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. *Cancer Research*, 76(11):3156-65.
76. Wang W, Kryczek I, Dostál L, Lin H, Tan L, **Zhao L**, Lu F, Wei S, Maj T, Peng D, He G, Vatan L, Szeliga W, Kuick R, Kotarski J, Tarkowski R, Dou Y, Rattan R, Munkarah A, Liu JR, and Zou W. (2016). Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. *Cell*, 165(5):1092-105.
77. Xie J, **Zhao L**, Zhou S, and He Y. (2016). Statistical and Ontological Analysis of Adverse Events Associated with Monovalent and Combination Vaccines Against Hepatitis A and B Diseases. *Scientific Report*, 6:3418.
78. Guo A, Racz R, Hur J, Lin Y, Xiang Z, **Zhao L**, Rinder J, Jiang G, Zhu Q, and He Y. (2016). Ontology-based Collection, Representation and Analysis of Drug-Associated Neuropathy Adverse Events. *Journal of Biomedical Semantics*, 7:29

79. Koschmann C, Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, Mendez F, Kamran N, Dzaman M, Mulpuri L, Krasinkiewicz J, Doherty R, Lemons R, Brosnan-Cashman JA, Li Y, Roh S, **Zhao L**, Appelman H, Ferguson D, Gorbunova V, Meeker A, Jones C, Lowenstein PR, and Castro MG. (2016). ATRX Loss Promotes Tumor Growth and Impairs Nonhomologous End Joining DNA Repair in Glioma. *Sci Transl Med*, 8(328):328ra28.
80. Nagarsheth N, Peng D, Kryczek I, Wu K, Li W, Zhao E, **Zhao L**, Wei S, Frankel T, Vatan L, Szeliga W, Dou Y, Owens S, Marquez V, Tao K, Huang E, Wang G, and Zou W. (2016). PRC2 Epigenetically Silences Th1-type Chemokines to Suppress Effector T cell Trafficking in Colon Cancer. *Cancer Research*, 76(2):275-82.
81. Zhao E, Maj T, Kryczek I, Li W, Wu K, **Zhao L**, Wei S, Crespo J, Wan S, Vatan L, Szeliga W, Shao I, Wang Y, Liu Y, Varambally S, Chinnaiyan AM, Welling TH, Marquez V, Kotarski J, Wang H, Wang Z, Zhang Y, Liu R, Wang G, and Zou W. (2016). Cancer Mediates Effector T Cell Dysfunction by Targeting MicroRNAs and EZH2 via Glycolysis Restriction. *Nature Immunology*, 17(1):95-103.
82. Reddy RM, Murlidhar V, **Zhao L**, Grabauskiene S, Zhang Z, Ramnath N, Lin J, Chang AC, Carrott P, Lynch W, Orringer MB, Beer DG, and Nagrath S. (2016). Pulmonary venous Blood Sampling Significantly Increases the Yield of Circulating Tumor Cells in Early-stage Lung cancer. *J Thorac Cardiovasc Surg*, 151(3):852-857.
83. Raghunathan R, Cease K, Troeschel S, **Zhao L**, Gross M, Chen G, Chopra V, and Ramnath N. (2016). Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*.
84. **Zhao L**, Shi J, Shearon TH, and Li Y. (2015). A Dirichlet Process Mixture Model for Survival Outcome Data: Assessing Nationwide Kidney Transplant Centers. *Statistics in Medicine*, 34(8): 1404-1416.
85. **Zhao L**, Feng D, Neelon B and Buyse M. (2015). Evaluation of Treatment Efficacy Using a Bayesian Mixture Piecewise Linear Model of Longitudinal Biomarkers. *Statistics in Medicine*, 34(10): 1733-1746.
86. Peng D, Kryczek I, Nagarsheth N, **Zhao L**, Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, Kotarski J, Tarkowski R, Dou Y, Cho K, Hensley-Alford S, Munkarah A, Liu R, and Zou W. (2015). Epigenetic Silencing of TH1-type Chemokines Shapes Tumour Immunity and Immunotherapy. *Nature*, 527(7577): 249-253.
87. Swiecicki PL, **Zhao L**, Belile E, Sacco AG, Chepeha DB, Dobrosotskaya I, Spector M, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey T, and Worden FP. (2015). A Phase II Study Evaluating Axitinib in Patients with Unresectable, Recurrent or Metastatic Head and Neck Cancer. *Invest New Drugs*, 33(6):1248-56.
88. Walters LL, Pang JC, **Zhao L**, Jorns JM. (2015). Ductal Carcinoma in Situ with Distorting Sclerosis on Core Biopsy May be Predictive of Upstaging on Excision. *Histopathology*, 66(4):577-586.

89. Davis EJ, Chugh R, **Zhao L**, Lucas DR, Biermann JS, Zalupski MM, Feng M, Wong SL, Jacobson J, Zyczynski L, Reinke D, Metko G, Baker LH, and Schuetze SM. (2015). A Randomised, Open-label, Phase II Study of Neo/adjuvant Doxorubicin and Ifosfamide Versus Gemcitabine and Docetaxel in Patients with Localised, High-risk, Soft Tissue Sarcoma. *Eur J Cancer*. 51(13):1794-1802.
90. Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, **Zhao L**, Maybaum J, Lawrence TS, and Morgan MA. (2015). Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. *Neoplasia*,17(10): 757–766.
91. Khondee S, Rabinsky EF, Owens SR, Joshi BP, Qiu Z, Duan X, **Zhao L**, and Wang TD. (2015) Targeted Therapy of Colorectal Neoplasia with Rapamycin in Peptide-labeled Pegylated Octadecyl Lithocholate Micelles. *J Control Release*, 199: 114-121.
92. Bachman, MA, Breen P, Deornellas V, Mu Q, **Zhao L**, Wu W, Cavalcoli JD, and Mobley HLT. (2015). Genome-Wide Identification of Klebsiella pneumoniae Fitness Genes during Lung Infection. *mBio*, 6(3): e00775-15.
93. Kantola S, Virani N, Haus C, Hipp J, **Zhao L** and Jing X. (2015). Prospective Evaluation of Impact of Using The Bethesda System for Reporting Thyroid Cytopathology: An Institutional Experience. *Journal of the American Society of Cytopathology*, 4: 25-29.
94. Xie CM, Wei D, **Zhao L**, Marchetto S, Mei L, Borg JP, and Sun Y. (2015). Erbin is a novel substrate of Sag-TrCP E3 ligase that regulates KrasG12D-induced skin tumorigenesis. *J. Cell Biol*, 209(5):721-37.
95. **Zhao L**, Feng D, Bellile E and Taylor JMG. (2014). Bayesian Random Threshold Estimation in a Cox Proportional Hazards Cure Model. *Statistics in Medicine*, 33(4):650-661.
96. Ghannam M, **Zhao L**, and Reddy RM. (2014). Current Interest in Careers in Surgery and Cardiothoracic Surgery from the Millennial Generation. *J Surg Educ*:71(5):668-73.
97. Nadal E, Chen G, Prensner JR, Shiratsuchi H, Sam C, **Zhao L**, Kalemkerian GP, Brenner D, Lin J, Reddy RM, Chang AC, Capellá G, Cardenal F, Beer DG and Ramnath N. (2014). KRAS-G12C Mutation is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. *Journal of Thoracic Oncology*, 9(10): 1513-1522.
98. Jiang Y, Djuric Z, Sen A, Ren J, Kuklev D, Waters I, **Zhao L**, Uhlson CL, Hong YH, Murphy RC, Normolle DP, Smith WL and Brenner DE.(2014). Biomarker for Personalizing Omega-3 Fatty Acid Dosing. *Cancer Prevention Research*, 7(10):1011-1022.
99. Arps DP, Jorns JM, **Zhao L**, Bensenhaver J, Kleer CG and Pang JC. (2014). Re-excision Rates of Invasive Ductal Carcinoma with Lobular Features Compared with Invasive Ductal Carcinomas and Invasive Lobular Carcinomas of the Breast. *Annals of Surgical Oncology*, 21:4152–4158.
100. Brown NA, Rolland DC, McHugh JB, Weigelin HC, **Zhao L**, Lim MS, Elenitoba-Johnson KS, and Betz BL. (2014). Activating FGFR2-RAS-BRAF Mutations in Ameloblastoma. *Clinical Cancer Research*, 20(21): 5517–26.

101. Karnak D, Engelke C, Parsels LA, Kausar T, Wei D, Robertson J, Marsh K, Davis M, **Zhao L**, Maybaum J, Lawrence TS and Morgan MA. (2014). Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer. *Clinical Cancer Research*, 20(19):5085-5096.
102. Ahsan A, Ramanand SG, Bergin IL, **Zhao L**, Whitehead CE, Rehemtulla A, Ray D, Pratt WB, Lawrence TS, and Nyati MK. (2014). Efficacy of an EGFR-specific Peptide Against EGFR-dependent Cancer Cell Lines and Tumor Xenografts. *Neoplasia*, 16(2):105-14.
103. Kiel MJ, Velusamy T, Rolland D, Sahasrabudde A, Chung F, Bailey N, Schrader A, Li B, Li J, Ozel A, Betz B, Miranda R, Medeiros LJ, **Zhao L**, Herling M, Lim MS, and Elenitoba-Johnson KS. (2014). Integrated Genomic Sequencing Reveals Mutational Landscape of T-cell Prolymphocytic Leukemia. *Blood*, 124(9):1460-72.
104. Kryczek I, Lin Y, Nagarsheth N, Peng D, **Zhao L**, Zhao E et al. (2014). IL-22+CD4+ T Cells Promote Colorectal Cancer Stemness via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L. *Immunity*, 40(5):772-84.
105. Lu JC, Connelly JA, **Zhao L** et al. (2014). Strain Measurement by Cardiovascular Magnetic Resonance in Pediatric Cancer Survivors: Validation of Feature Tracking Against Harmonic Phase Imaging. *Pediatric Radiology*, 44: 1070-1076.
106. Li H, Tan M, Jia L, Wei D, Zhao Y, Chen G, Xu J, **Zhao L** et al. (2014). Inactivation of SAG/RBX2 E3 Ubiquitin Ligase Suppresses KrasG12D-driven Tumorigenesis. *The Journal of Clinical Investigation*, 124(2):835-846.
107. Cui T, Kryczek I, **Zhao L**, Zhao E, Kuick R, Roh M et al. (2013). Myeloid-derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2.. *Immunity*, 39(3): 611-621.
108. Engelke CG, Parsels LA, Qian Y, Zhang Q, Karnak D, Robertson JR, Wei D, Davis MA, Parsels JD, Tanska DM, **Zhao L** et al. (2013). Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor, MK8776. *Clinical Cancer Research*, 19(16):4412-21.
109. VanderVeen N, Paran C, Krasinkiewicz J, **Zhao L** et al. (2013). Effectiveness and Preclinical Safety Profile of Doxycycline to be Used 'Off-label' to Induce Therapeutic Transgene Expression in a Phase I Clinical Trial for Glioma. *Hum Gene Ther Clin Dev*, 24(3):116-26.
110. Hoodin F, **Zhao L**, Carey J, Levine JE, and Kitko C. (2013). Impact of Psychological Screening on Routine Outpatient Care of Hematopoietic Cell Transplantation Survivors Biology of Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, 19(10):1493-1497.
111. Wei D, Parsels LA, Karnak D, Davis MA, Parsels JD, **Zhao L** et al. (2013). Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair. *Clinical Cancer Research*, 19(16):4422-32.

112. Sheetz KH, **Zhao L**, Holcombe SA, Wang SC, Reddy RM, Lin MB et al. (2013). Decreased Core Muscle Size is Associated with Worse Patient Survival Following Esophagectomy for Cancer. *Dis Esophagus*, 26(7):716-22.
113. Jorns JM, Healy P and **Zhao L**. (2013). Review of Estrogen Receptor, Progesterone Receptor, and HER-2/neu Immunohistochemistry Impacts on Treatment for a Small Subset of Breast Cancer Patients Transferring Care to Another Institution. *Arch Pathol Lab Med*, 137(11):1660-2003.
114. Arps DP, Healy P, **Zhao L**, Klee CG and Pang JC. (2013). Invasive Ductal Carcinoma with Lobular Features: a Comparison Study to Invasive Ductal and Invasive Lobular Carcinomas of the Breast. *Breast Cancer Res Treat*, 138(3):719-26.
115. **Zhao L** and Banerjee M. (2012). Bayesian Piecewise Mixture Model for Racial Disparity in Prostate Cancer. *Computational Statistics and Data Analysis*, 56(2):362-369.
116. **Zhao L**, Taylor JMG, and Schuetze SM. (2012). Bayesian Decision Theoretic Two-stage Design in Phase II Clinical Trials with Survival Endpoints, *Statistics in Medicine*, 31(17):1804-1820.
117. Venkatesha VA, Parsels LA, Parsels JD, **Zhao L**, Zabludoff SD, Simeone D et al. (2012). Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition. *Neoplasia*, 14:519-25.
118. Kiel MJ, Velusamy T, Betz BL, **Zhao L**, Weigelin HG, Chiang MY et al. (2012). Whole-genome Sequencing Identifies Recurrent Somatic NOTCH2 Mutations in Splenic Marginal Zone Lymphoma. *J Exp Med.*, 209(9) 1553-65.
119. Schuetze SM, **Zhao L**, Chugh R et al. (2012). Results of a Phase II Study of Sirolimus and Cyclophosphamide in Patients with Advanced Sarcoma. *Eur J Cancer*, 48(9):1347-53.
120. Teman N, Silski L, **Zhao L**, Kober M, Urba SC, Orringer MB et al.(2012). Thromboembolic Events During Neoadjuvant Treatment of Esophageal Cancer Delay Time to Surgery. *Ann Thorac Surg*, 94(4):1118-25.
121. Kim SH, Chen G, King AN, Jeon CK, Christensen PJ, **Zhao L** et al. (2012). Characterization of Vitamin D Receptor (VDR) in Lung Adenocarcinoma. *Lung Cancer*,77(2):265-71.
122. **Zhao L**, Morgan MA, Parsels LA, Maybaum J, Lawrence TS, and Normolle D. (2011). Bayesian Hierarchical Change-point Methods in Modeling the Tumor Growth Profiles in Xenograft Experiments (with discussions). *Clinical Cancer Research*, 17(5): 1-7.
123. **Zhao L**, Morgan MA, Parsels LA, Maybaum J, Lawrence TS, and Normolle D. (2011). Response to Letter from Bassukas. *Clinical Cancer Research*, 17: 4613.
124. **Zhao L**, Lee J, Mody, R and Braun TM.(2011). The Superiority of the Time-to-Event Continual Reassessment Method to the Rolling Six Design in Pediatric Phase I Cancer Trials. *Clinical Trials*, 8(4):361-369.
125. Wei DP, Li H, Yu J, Sebolt JT, **Zhao L**, Lawrence TS et al. (2011). Radiosensitization of Human Pancreatic Cancer Cells by MLN4924, an Investigational NEDD8-activating Enzyme Inhibitor. *Cancer Research*, 72(1): 282-93.

126. Vance S, Liu E, **Zhao L**, Parsels J, Parsels L, Brown J et al. (2011). Selective Radiosensitization of p53 Mutant Pancreatic Cancer Cells by Combined Inhibition of Chk1 and PARP1. *Cell Cycle*, 10:4321-29.
127. Ray D, Ahsan A, Helman A, Chen G, Hegde A, Gurjar SR, **Zhao L**, Kiyokawa H, Beer DG, Lawrence TS, and Nyati MK. (2011). Regulation of EGFR Protein Stability by the HECT-type Ubiquitin Ligase MURF2. *Neoplasia*,13(7):570-578.
128. Parsels L, Qian Y, Tanska D, Gross M, **Zhao L**, Hassan M, et al. (2011). Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition. *Clinical Cancer Research*, 17:3706-15.
129. Davis SJ, **Zhao L**, Chang A and Orringer M. Refractory Cervical Esophagogastric Anastomotic Strictures: Management and Outcomes. (2011). *Journal of Thoracic and Cardiovascular Surgery*, 141:444-448.
130. Lao CD, Johnson T, Sondak VK, Lowe L, Kim DS, **Zhao L**, Naftanel M, Olsen S, Brenner DE. Feasibility of Serial Biopsies of Large Dysplastic Nevi as a Melanoma Chemoprevention Model. *J Am Acad Dermatol.*, 64(6):1188-90,2011
131. Chen G, Kim SH, King A, **Zhao L**, et.al. (2011). CYP24A1 Is an Independent Prognostic Marker of Survival in Patients with Lung Adenocarcinoma. *Clinical Cancer Research*, 17: 817-826.
132. Tan L, Kwok RP, Shukla A, Kshirsagar M, **Zhao L**, et al. (2011). Trichostatin a Restores Apaf-1 Function in Chemoresistant Ovarian Cancer Cells. *Cancer*, 4: 784-794.
133. Bhojani MS, Nyati MK, **Zhao L**, Normolle, DP, Ross BD, Lawrence TS, and Rehemtulla A. (2011). Molecular Imaging of Akt Enables Early Prediction of Response to Molecular Targeted Therapy. *Transl Oncol*, 4(3): 122-125.
134. Morgan MA, Parsles LA, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, **Zhao L**, et al. (2010). Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2 Checkpoint and Inhibition of Homologous Recombinational DNA Repair. *Cancer Research*, 70(12):4972-4981.
135. Jing X, Roh, M, Knoepp S, **Zhao L**, and Michael C. (2010). Follicular Lesion of Undetermined Significance and Identifying Predictive Features for Neoplasia. *Diagnostic Cytopathology*,39(10):737-42.
136. Ning W. and **Zhao L**. (2010). A Moment-based Test for the Mixture Distributions with Small Sample Sizes and its Application. *Far East Journal of Theoretical Statistics*, 33(1): 23-29.
137. Anderson MA, Brenner DE, Scheiman JM, Simeone DM, Singh N, Sikora MJ, **Zhao L**, Mertens AN, and Rae JM (2010). Reliable Gene Expression Measurements from Endoscopic Fine Needle Aspirates of Pancreatic Tumors: Effect of Amplicon Length and Quality Assessment. *Journal of Molecular Diagnostics*, 12(5): 566-575.
138. **Zhao L** and Woodworth G. (2009). Bayesian Decision-Theoretic Group Sequential Analysis with Survival Endpoints. *Statistics in Medicine*, 28:1339-1352.

139. Stoffel E, Turgeon D, Stockwell D, **Zhao L**, et al. (2008). Missed Adenomas during Colonoscopic Surveillance in Individuals with Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer). *Cancer Prevention Research*, 1, 470-475.
140. Moon J, Kuehn D, Chen G, and **Zhao L**. (2007). Induced Velopharyngeal Fatigue Effects in Speakers with Repaired Palatal Clefts. *The Cleft Palate-Craniofacial Journal*, 44, 251-260.

Teaching Experience:

- 2015-2016 BIostat 524: Biostatistics for Clinical Researchers (25 students)
Instructor, Dept of Biostatistics, University of Michigan
 Median scores are 4.05 and 4.00 for Q_1 and Q_2 , respectively
- 2016-2017 BIostat 523: Statistical Methods for Epidemiology (25 students)
Instructor, Dept of Biostatistics, University of Michigan
 Median scores are 4.38 and 4.79 for Q_1 and Q_2 , respectively
- 2017-2018 BIostat 524: Biostatistics for Clinical Researchers (22 students)
Instructor, Dept of Biostatistics, University of Michigan
 Mean scores are 4.86 and 4.71 for Q_1 and Q_2 , respectively
- 2018-2019 BIostat 523: Statistical Methods for Epidemiology (22 students)
Instructor, Dept of Biostatistics, University of Michigan
 Mean scores are 4.86 and 4.86 for Q_1 and Q_2 , respectively
- 2019-2020 BIostat 524: Biostatistics for Clinical Researchers (29 students)
Instructor, Dept of Biostatistics, University of Michigan
- 2020-2021 BIostat 523: Statistical Methods for Epidemiology (29 students)
Instructor, Dept of Biostatistics, University of Michigan

Q_1 : Overall, this was an excellent course (1: Strongly Disagree to 5: Strongly Agree)

Q_2 : Overall, the instructor was an excellent teacher (1: Strongly Disagree to 5: Strongly Agree)

Current Grants:

National Institutes of Health R01-AI158543-01 01/11/20-12/31/25

Role: PI

Incorporation of multilevel ontologies of adverse events and vaccines for vaccine safety surveillance. (\$374,998, 25% Effort)

Michigan Institute for Clinical and Health Research (MICHR) U-Award 01/01/20-12/31/20

Role: PI

Incorporation of multilevel adverse event ontology for vaccine safety surveillance. (\$15,000)

MIDAS PODS grants 01/01/20-12/31/20

Role: PI

Incorporation of multilevel adverse event ontology for vaccine safety surveillance. (\$60,000)

Michigan Institute for Clinical and Health Research (MICHR) U-Award 01/01/18-12/31/18
Role: PI
Dynamic Risk Prediction Using Longitudinal Biomarkers of High Dimension. (\$15,000)

National Institutes of Health R01 CA208335-01A1 03/03/17-02/28/22
Role: Co-investigator
Label free microfluidic isolation, characterization and ex vivo expansion of CTCs. P.I. Na-grath, S. (\$368,261, 10% Effort)

National Institutes of Health R01 AI125307-01A1 02/15/17-01/31/22
Role: Co-investigator
Integrated modeling of Klebsiella pneumoniae infections based on bacterial genotype, patient factors and colonization status. P.I. Bachman, MA. (\$412,729, 10% Effort)

National Institutes of Health R01-CA171306-03 04/01/2018-03/31/2023
Role: Co-investigator
Role of Cdc73 in normal hematopoiesis and identify PAFc protein interactions differentially required in leukemia. P.I. Muntean A. (\$1,250,000, 3% Effort)

National Institutes of Health R01-094573 12/1/2017-11/30/22
Role: Co-investigator
Interactions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas. P.I. Castro M. (\$359,888, 4% Effort)

National Institutes of Health to be funded for 4 years
Role: Co-investigator
Targeting Chemoreceptor Control of Breathing during Sleep to Mitigate Opioid-Associated Sleep Disordered Breathing. P.I. Chowdhuri S. (5% Effort)

National Institutes of Health 1 U24 DK122927-01 07/01/19-06/30/22
Role: Co-investigator
University of Michigan Data Coordinating Center for the Diabetic Foot Consortium. P.I. Spino C. (\$561,450, 5% Effort)

National Institutes of Health 1-R01-AI134731-01A1 09/01/18-08/31/23
Role: Co-investigator
Fitness of gram-negative pathogens during bacteremia. P.I. Mobley H. (\$514,746,10% Effort)

National Institutes of Health 1 R21 NS114749-01 09/01/19-09/31/21
Role: Co-investigator
Vigor and the LDR in Parkinson disease. P.I. Albin R. (\$390,000, 2% Effort)

National Institutes of Health 1K08CA234222-01 09/01/18-08/31/22
Role: Co-investigator
Linking epigenetic regulation and TGF- β signaling in pancreatic cancer. P.I. Shi J. (\$767,761, 0% Effort)

Completed Grants:

Department of Defense CA170922 7/15/2008-7/14/2020

Role: Co-investigator
 Establish a specific class of small RNAs as potential biomarkers of colorectal cancer and to understand their immunomodulatory activity. P.I. Chen G. (\$400,000, 10% Effort)

National Institutes of Health R01CA193136-01A1 7/01/15-06/30/20
 Role: Co-investigator
 MDSCs in Ovarian Cancer. P.I. Zou, W. (\$321,456, 3% Effort)

National Institutes of Health R01-CA171306-03 07/01/13-06/30/18
 Role: Co-investigator
 Immune Regulation in the Microenvironment of Oropharyngeal Cancer. P.I. Zou, W. (\$375,303, 2.3% Effort)

National Institutes of Health R33 CA202867 4/15/16-3/31/19
 Role: Co-investigator
 High Throughput GO Chip isolation of Lung CTCs for Molecular Diagnosis and Drug Testing. P.I. Nagrath, S. (\$226,737, 10% Effort)

Michigan Institute for Clinical and Health Research (MICHR) UL1-TR002240 6/1/17-2/28/18
 Role: Primary-investigator
 Dynamic Risk Prediction Using Longitudinal Biomarkers of High Dimensions (\$15,000)
 National Institutes of Health R21 CA205636-01 04/01/16-03/31/18
 Role: Co-investigator
 The Gut Microbiome and Responses to Neoadjuvant Chemoradiation in Rectal Cancer Patients. P.I. Chen, G. (\$117,450, 4.3% Effort)

National Institutes of Health R21-CA-191744-02 12/18/14-11/30/17
 Role: Co-investigator
 Identifying bacterial regulators of tumorigenesis. P.I. Chen, G. & Lubman D. (\$108,750, 3.8% Effort)

National Institutes of Health R01-CA166879-04 01/18/13-12/31/17
 Role: Co-investigator
 Regulation of intestinal inflammation and tumorigenesis. P.I. Chen, G. (\$270,500, 1% Effort)

National Institutes of Health/NIAID R01-AI087128 9/1/09-8/31/13
 Role: Co-investigator
 DEK and TNF Inhibitors in Juvenile Arthritis. P.I. Markovitz, D. (\$250,000, 10% Effort)

National Institutes of Health P50-CA-130810-01A2 09/1/16-08/31/17
 Role: Co-investigator
 Translational Research in GI Cancer. P.I. Brenner, D. (\$1,551,905, 9% Effort)

Michigan Institute for Clinical and Health Research 9/1/09-8/31/10
 Role: Co-investigator
 DEK Oncoprotein as a Therapeutic Target in Melanoma. P.I. Markovitz, D. (\$50,000, 2% Effort)

VA Merit Award 05/01/10 - 04/30/13

Role: Co-investigator

The role of Vitamin D metabolism in Non-Small Cell Lung Cancer. P.I. Ramnath, N. (\$146,706, 10% Effort)

NIH/NCI K08 CA133185

9/16/2008-8/31/2012

Role: Co-investigator

Role of the immune receptor Nod1 in inflammation-associated colon tumorigenesis. P.I. Chen, G. (\$532,480, 5% Effort)

National Institutes of Health R01 CA131290

03/01/09 –02/28/14

Role: Co-investigator

Integration of EGFR Inhibitors with Radiochemotherapy in Head and Neck Cancer. P.I. Chen, G. (\$204,560, 4% Effort)

National Institute of Health U54 CA163059

09/01/11 - 08/31/16

Role: Co-investigator

Early Detection of Cancer in Barrett's Esophagus Role. P.I. Wang, T & Beer, D. (\$830,151, 0% Effort)

National Institutes of Health R01 CA156744-01

05/11/11-03/31/16

Role: Co-investigator

SCF E3 ligase as a cancer and radiosensitizing target. P.I. Sun, Y. (\$207,500, 2.5% Effort)

Talks and Presentations:

Invited Talks:

1. Bayesian Hierarchical Change-point Methods in Modeling the Tumor Growth Profiles in Xenograft Experiments. *Department of Mathematics and Statistics, Bowling Green State University*. October 2009. Bowling Green, OH, USA.
2. Bayesian Decision Sequential Analysis with Survival Endpoint in Phase II Clinical Trials. *Bayesian Biostatistics Conference, MD Anderson Cancer Center*. January 2010. Houston, TX, USA.
3. Bayesian Two-stage Design in Phase II Clinical Trials with Time-to-event Endpoint: A Simulation-based Decision-theoretic Approach. *Third IWSM Conference, Stanford University*. June 2011. Stanford, CA, USA.
4. Bayesian Hierarchical Change-point Methods in Modeling the Tumor Growth Profiles in Xenograft Experiments. *School of Mathematical Sciences, University of Chinese Academy of Sciences*. June 2013. Beijing, China.
5. Bayesian Two-stage Design in Phase II Clinical Trials with Time-to-event Endpoint: A Simulation-based Decision-theoretic Approach. *Joint Applied Statistics Symposium of International Chinese Statistical Association and Korean International Statistical Society*. June 2014. Portland, OR, USA.
6. Evaluation of Treatment Efficacy using a Bayesian Mixture Piecewise Linear Model of Longitudinal Biomarkers. *School of Mathematics and Statistics, Beijing Institute of Technology*. January, 2015. Beijing, China.

7. Evaluation of Treatment Efficacy using a Bayesian Mixture Piecewise Linear Model of Longitudinal Biomarkers. *School of Mathematical Sciences, University of Chinese Academy of Sciences*. January 2015. Beijing, China.
8. Evaluation of Treatment Efficacy using a Bayesian Mixture Piecewise Linear Model of Longitudinal Biomarkers. *Applied statistics symposium ICSA*. 2016. Atlanta, GA
9. Innovative Designs for Clinical Trials. *1-hr Webinar cosponsored by ASA CT Chapter and Boehringer Ingelheim*. July, 2017. USA.
10. Identification of Conditionally Essential Genes in Transposon Sequencing Studies. *Tools and Technology Seminar, Department of Computational Medicine & Bioinformatics, University of Michigan*. January, 2018. USA.

Contributed Talks:

11. Bayesian Sequential Analysis for Survival Data. *Joint Statistical Meetings*. August 2006. Seattle, Washington, USA.
12. Bayesian Two-stage Design in Phase II Clinical Trials with Time-to-event Endpoint: A Simulation-based Decision-theoretic Approach. *Annual Bayesian Biostatistics Conference, MD Anderson Cancer Center*. January 2012. Houston, TX, USA.
13. Bayesian Two-stage Design in Phase II Clinical Trials with Time-to-event Endpoint: A Simulation-based Decision-theoretic Approach. *IMS-China International Conference*. July 2013. Chengdu, China.
14. Evaluation of Treatment Efficacy using a Bayesian Mixture Piecewise Linear Model of Longitudinal Biomarkers. *Joint Statistical Meetings*. August 2015, Seattle, Washington, USA.
15. Analysis of RNA-Seq Data Using a Family of Negative Binomial Models. *Joint Statistical Meetings*. August, 2016. Chicago, IL, USA.
16. Identification of Conditionally Essential Genes in Transposon Sequencing Studies. *Joint Statistical Meetings*. August, 2017. Baltimore, MD, USA.
17. Identification of Essential Genes in Transposon Sequencing Studies. *Eastern North American Region meeting*. March, 2018. Atlanta, GA, USA.
18. Dynamic Risk Prediction Using Longitudinal Biomarkers of High Dimensions. *Eastern North American Region meeting*. March, 2019. Philadelphia, PA, USA.
19. Deep Neural Networks for Survival Analysis Using Pseudo Values. *Eastern North American Region meeting*. March, 2020. Virtual meeting, USA.

Student and Fellow Advising:

- Member, Doctoral Dissertation Committee. Ming Teng (Biostatistics, graduated in 2017, Chair: Timothy Johnson)

- Supervisor for Research Assistant. Bangyao Zhao (Biostatitics), 2020-present. Yiyuan Huang (Biostatitics), 2020-present. Yajing Li (Biostatitics), 2020. Peiyao Zhao (Biostatitics), 2020. Xuan Chen (Biostatitics), 2020-present. Menghan Lin (Statistics), 2019-2020. Shuoran Li (Statistics), 2019-2020. Zhenbang Jiao (Statistics), 2019-2020. 2019-2020. Tuo Wang (Statistics), 2017-2018. Emily Roberts (Biostatistics), 2017-2018. Stephen Salerno (Biostatistics), 2017-2018. Jordan Rinder (Medical School), 2016. Anita Pandit (Biostatistics), Summer 2015. Jingchunzi Shi 2013. Patrick Healy (Biostatistics), 2012.
- Academic Advisor. Masters Student. Yiwen Lu (Biostatistics), 2015-2016

Professional Service:

Editorial Activities:

Journal Referee Ain Shams Engineering Journal
Annals of Human Genetics
Annals of Oncology
Bioinformatics
Biometrical Journal
Biometrics
BMC Bioinformatics
BMC Pediatrics
BMC Cancer
BMC Medical Research Methodology
Cancer Biomarkers
Clinical Cancer Research
Computer Methods and Programs in Biomedicine
Contemporary Clinical Trials
Future Science
IEEE Transactions on Neural Networks and Learning Systems
International Statistical Review
International Journal of Radiation Oncology, Biology, Physics
Journal of Applied Statistics
Journal of Biopharmaceutical Statistics
Journal of Clinical Oncology
Journal of Machine Learning Research
Journal of the American Statistical Association
Journal of Statistical Computation and Simulation
Pharmaceutical Statistics
Physics in Medicine and Biology
PLOS Computational Biology
PLOS ONE
Physics in Medicine and Biology
Statistics in Medicine
Statistical Modeling
Statistical Applications in Genetics and Molecular Biology

Book Referee:

- Bayesian Methods in Epidemiology, by Lyle D. Broemeling, *Chapman & Hall/CRC*, 2014.
- Modern Adaptive Randomized Clinical Trials – statistical and practical aspects, by Oleksandr Sverdlov, *Chapman & Hall/CRC*, 2015
- Current Trends in Bayesian Methodology with Applications, by Satyanshu Kumar Upadhyay, Umesh Singh, Dipak K. Dey, and Appaia Loganathan, *Chapman & Hall/CRC*, 2015
- Generalized Principal Component Analysis, by Rene Vidal, Yi Ma, S. Shankar Sastry, *Chapman & Hall/CRC*, 2016.

- Extreme Value Modeling and Risk Analysis, by Dipak K. Dey and Jun Yan, *Chapman & Hall/CRC*, 2016
- Statistical Methods for Survival Trial Design and Monitoring: with Application to Cancer Clinical Trials (book proposal), by Jianrong Wu, *Chapman & Hall/CRC*, 2016
- Noninferiority Testing in Clinical Trials, by Tie-Hua Ng, *Chapman & Hall/CRC*, 2017,
- SAS for Mixed Models: Introduction and Basic Applications, by Walter W. Stroup, George A. Milliken, and Elizabeth A. Claassen and Russell D. Wolfinger, *Chapman & Hall/CRC*, 2019.

Grant Referee:

- NSA-AMS grant, 2014
- NIH reviewer- NEI Special Emphasis Panel, March 2020
- NIH reviewer- NEI K Award, June 2020
- NIH reviewer- NEI Clinical Research Grant, October 2020

Service to the Profession at Large:

- **Committee Member:** Regional Advisory Board for Eastern North American Regional Meeting of the International Biometric Society (2018-2021)
- **Organizing Committee Member:** The 4th COPSS-NISS COVID-19 Data Science Webinar
- **Organizer:** WebENAR series 2019-2020
- **Chair:** Invited Session on “*Phase I clinical trials*”. Third IWSM Conference, Stanford University, June 2011. Stanford, CA, USA.
- **Organizer and Chair:** Invited Session on “*Nonparametric Bayesian Methods in Biostatistics*”. Joint Statistical Meetings (JSM). August, 2016. Chicago, IL, USA.
- **Chair:** Invited Session on “*Integrative Modeling of Heterogeneous Data*”. A Conference in Celebration of Jeremy Taylor’s 60th Birthday , June 2017. Ann Arbor, MI, USA.
- **Organizer and Chair:** Invited Session on “*Recent Advances for estimating covariance/precision matrix*”. Eastern North American Region (ENAR) meeting, March 2018. Atlanta, GA, USA.
- **Chair:** Invited Session on “*Invited Session: Advances in Bayesian Statistics*”. Fifth Bayesian, Fiducial, and Frequentist (BFF5) Conference, May 2018. Ann Arbor, MI, USA.
- **Chair:** Invited Session on “*Contributed Session: Comparative effectiveness, clustered and categorical data*”. Eastern North American Region (ENAR) meeting, March 2019. Philadelphia, PA, USA.

- **Organizer and Chair:** Invited Session on “*Modern Graphical Modeling of Complex Biomedical Systems*”. Eastern North American Region (ENAR) meeting, March 2020. Virtual meeting.
- **Organizer:** Invited Session on “*Modern Graphical Modeling of Complex Biomedical Systems*”. Joint Statistical Meetings (JSM), August 2020. Virtual meeting.
- **Organizer and Chair:** Invited Talk by Bhramar Mukherjee on “*Predictions, Role of Interventions and the crisis of virus in India*”. The 4th COPSS-NISS COVID-19 Data Science Webinar.
- **Organizer and Chair:** Invited Session on “*2) The Promise and Pitfalls of Pragmatic Trials Utilizing Real-World Evidence* ”. Eastern North American Region (ENAR) meeting, March 2021. Virtual meeting.
- **Organizer and Chair:** Invited Session on “*2) The Promise and Pitfalls of Pragmatic Trials Utilizing Real-World Evidence* ”. Joint Statistical Meetings (JSM), August 2021. Virtual meeting.

Service at the University of Michigan:

- Member of the Quality Assurance Review Committee on investigator-initiated clinical trials at the University of Michigan Cancer Center. 2010-2013.
- Organize and participate in the Hematology/Oncology journal club, School of Medicine, University of Michigan, Ann Arbor. 2011-2018.
- Computing/Web Committee, Department of Biostatistics, University of Michigan, Ann Arbor. 2014-2015.
- Clinical Training/OJOC Committee, Department of Biostatistics, University of Michigan, Ann Arbor. 2015-2020.
- Member of Protocol Review Committee, Rogel Cancer Center, university of Michigan. 2019-present.

Professional Membership:

- 2006-present American Statistical Association
- 2011-present International Society for Bayesian Analysis
- 2013-present International Chinese Statistical Association
- 2017-present Eastern North American Region, International Biometric Society